Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

SED Pack: Safety and Performance of a Medical Device Software for Predictive Monitoring During Sedation

4. august 2026 oppdatert av: Predictheon Medical, S.L.

Prospective Observational Clinical Investigation to Evaluate the Clinical Performance and Safety of a Medical Device Software (SED Pack) During Standard Procedural Sedation

The SED-PACK study is a prospective, observational, single-center clinical investigation evaluating the clinical performance and safety of SED Pack, a Medical Device Software (MDSW) developed by Predictheon Medical S.L., in a fully blinded, non-interventional setting during routine procedural sedation in adult patients at Hospital Clínic de Barcelona, Spain.

Procedural sedation consists in the administration of sedative and analgesic drugs to allow patients to undergo routine diagnostic or therapeutic procedures comfortably. Despite advances in monitoring technology, adverse events such as arterial hypotension, respiratory depression, or inadequate sedation remain frequent due to marked interindividual variability in drug response. Currently, clinicians rely on standard physiological monitoring that measures what is happening in real time but does not anticipate what is about to happen.

SED Pack is designed to address this gap by continuously processing physiological monitoring data and drug-infusion information to generate four real-time predictive indices (updated once per second): pSED (sedation depth), pNOC (likelihood of response to a noxious stimulus), pHYPO (likelihood of arterial hypotension), and pDEP (likelihood of respiratory depression).

In this clinical investigation, one hundred and twenty adult patients (≥18 years, ASA I-III) will be enrolled. Predictive performance is evaluated using the c-index for pSED, pHYPO, and pDEP, and AUC-ROC for pNOC. The primary hypothesis is that each index achieves a discrimination performance ≥0.70 (lower bound of the 95% CI also ≥0.70). The software runs in fully blinded mode: its predictions are not visible to clinicians and do not influence patient management. No additional procedures beyond standard clinical care are introduced.

The study complies with MDR 2017/745 and ISO 14155, with AEMPS authorization and CEIm approval (reference: HCB/2026/0307).

Expected outcomes include confirmation that each SED Pack predictive index achieves clinically acceptable discrimination performance, supporting the clinical use of this investigational software as a tool to anticipate and prevent sedation-related complications.

Studieoversikt

Detaljert beskrivelse

Investigational device: SED Pack is a Medical Device Software (MDSW) that continuously processes physiological monitoring data and drug-infusion parameters to generate four real-time predictive indices (scale 0-100, updated once per second): pSED (probability of sedation depth from light sedation to general anesthesia), pNOC (probability of motor response to mild noxious stimuli), pHYPO (probability of clinically relevant arterial hypotension), and pDEP (probability of clinically relevant respiratory depression). The software incorporates a predefined individualization step that adjusts patient-specific parameters within a fixed model structure based on observed physiological signals. This process is deterministic and does not involve adaptive learning, model retraining, or self-modification. The algorithmic structure, logic, and parameters are fully locked throughout the investigation.

Study design: Prospective, observational, single-arm, single-center clinical investigation conducted under Article 62 of Regulation (EU) 2017/745 at Hospital Clínic de Barcelona, Spain. The investigation is non-interventional: no additional procedures beyond standard clinical care are introduced. The SED Pack software is installed on a dedicated PC connected via wired, unidirectional, read-only serial interfaces to standard clinical monitoring systems; the PC is not connected to any wireless or hospital network during the investigation. The software operates in fully blinded mode throughout: its predictions are not visible to the attending anesthesiologist, endoscopist, nursing staff, or investigators performing clinical reference assessments, and there is no break-glass mechanism for real-time visualization. All clinical decisions rely exclusively on standard-of-care CE-marked monitoring systems.

Patient enrollment: Participants are recruited among adult patients scheduled for elective gastrointestinal endoscopic procedures requiring procedural sedation at Hospital Clínic de Barcelona. Potentially eligible patients are identified during routine pre-procedural evaluation, provided with a patient information sheet and an informed consent form, and enrolled only after written informed consent is obtained. Participation is entirely voluntary and refusal or withdrawal does not affect standard medical care. Because the investigation does not deviate from routine clinical practice and introduces no additional procedures or risks, no study-specific patient training is required.

Performance evaluation and statistical analysis: The primary objective is to evaluate the predictive performance of the four SED Pack indices (pSED, pNOC, pHYPO, and pDEP) against predefined clinical and physiological reference standards, using the concordance statistic (c-index) for pSED, pHYPO, and pDEP, and the AUC-ROC for pNOC, complemented by sensitivity and specificity analyses at predefined operational thresholds. Secondary objectives include evaluation of predictive performance at short-term prediction horizons (+5 and +10 minutes), threshold-based AUC-ROC analyses against predefined binary clinical thresholds, and exploratory subgroup analyses by ASA physical status, age group, and sex. One pre-planned interim analysis will be conducted after enrollment of approximately 50% of the target sample for data quality assessment purposes only.

The anticipated outcome of this investigation is the confirmation that the SED Pack predictive indices achieve clinically acceptable discrimination performance against predefined reference standards, supporting the clinical performance claims of this investigational software. Ultimately, SED Pack has the potential to transform the monitoring paradigm during procedural sedation by enabling clinicians to anticipate adverse events before they occur, improving patient safety and supporting more individualized drug management.

Studietype

Observasjonsmessig

Registrering (Antatt)

120

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

    • Barcelona
      • Barcelona, Barcelona, Spania, 08036
        • Rekruttering
        • Hospital Clinic de Barcelona
        • Ta kontakt med:
          • Julia Martínez Ocón, MD
          • Telefonnummer: 93 227 55 58
          • E-post: jocon@clinic.cat
        • Hovedetterforsker:
          • Julia Martínez Ocón, MD

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen
  • Eldre voksen

Tar imot friske frivillige

N/A

Prøvetakingsmetode

Sannsynlighetsprøve

Studiepopulasjon

Adult patients scheduled for elective, non-emergent gastrointestinal endoscopic procedures requiring standard procedural sedation with propofol and remifentanil via TCI at the Endoscopy Unit of Hospital Clínic de Barcelona, Spain. Patients are identified during routine pre-procedural evaluation and enrolled consecutively after provision of written informed consent.

Beskrivelse

Inclusion Criteria:

  • Age ≥18 years
  • ASA physical status I-III
  • Scheduled for an elective, non-emergent gastrointestinal endoscopic procedure
  • Procedural sedation planned with propofol and remifentanil administered via a target-controlled infusion (TCI) system
  • Administration of sedative and analgesic drugs via a peripheral venous line
  • Ability to understand the study information and provide written informed consent

Exclusion Criteria:

  • Presence of medical conditions or use of medications that, in the investigator's judgment, could significantly interfere with the interpretation of physiological signals used as reference standards (e.g., severe autonomic dysfunction, severe movement disorders).
  • Known severe neurologic, cardiovascular or respiratory disease that substantially alters baseline physiological monitoring or expected sedation response
  • ASA physical status IV, V or VI
  • Known or anticipated difficult airway requiring advanced airway management or interfering with standard respiratory monitoring
  • Requirement for central venous access for drug administration
  • Sedation performed outside the endoscopy unit (e.g., intensive care, emergency department)
  • Inability to understand study information, provide consent or cooperate with clinical assessments due to language barrier or cognitive impairment

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Discrimination Performance of pSED (Sedation Prediction Index)
Tidsramme: From the onset of procedural sedation to its completion, assessed continuously during each sedation session (estimated duration: 20 to 60 minutes per participant)
Concordance statistic (c-index) comparing continuous pSED predictions against an ordinal clinical sedation scale (OAA/S- and Ramsay-derived; Level 1: light/no sedation; Level 2: moderate sedation; Level 3: deep sedation; Level 4: general anesthesia) assessed every 5 minutes by the investigator.
From the onset of procedural sedation to its completion, assessed continuously during each sedation session (estimated duration: 20 to 60 minutes per participant)
Discrimination Performance of pNOC (Nociceptive Response Prediction Index)
Tidsramme: From the onset of procedural sedation to its completion, assessed at each endoscope insertion or manipulation event (estimated duration: 20 to 60 minutes per participant)
AUC-ROC comparing continuous pNOC predictions against a binary reference standard: presence or absence of motor response (gag reflex or involuntary limb movement) during endoscope insertion or manipulation.
From the onset of procedural sedation to its completion, assessed at each endoscope insertion or manipulation event (estimated duration: 20 to 60 minutes per participant)
Discrimination Performance of pHYPO (Hypotension Prediction Index)
Tidsramme: From the onset of procedural sedation to its completion, assessed continuously during each sedation session (estimated duration: 20 to 60 minutes per participant)
Concordance statistic (c-index) comparing continuous pHYPO predictions against non-invasive mean arterial pressure (MAP) measurements obtained at intervals not exceeding 5 minutes, using predefined hypotension thresholds (MAP <75, <65, and <55 mmHg).
From the onset of procedural sedation to its completion, assessed continuously during each sedation session (estimated duration: 20 to 60 minutes per participant)
Discrimination Performance of pDEP (Respiratory Depression Prediction Index)
Tidsramme: From the onset of procedural sedation to its completion, assessed continuously during each sedation session (estimated duration: 20 to 60 minutes per participant)
Concordance statistic (c-index) comparing continuous pDEP predictions against respiratory effort rate and tidal volume reference standard measurements, using predefined respiratory depression thresholds.
From the onset of procedural sedation to its completion, assessed continuously during each sedation session (estimated duration: 20 to 60 minutes per participant)

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Short-term Predictive Performance of pSED, pNOC, pHYPO, and pDEP at +5-Minute and +10-Minute Prediction Horizons
Tidsramme: From the onset of procedural sedation to its completion (estimated duration: 20 to 60 minutes per participant)
Concordance statistic (c-index) for pSED, pHYPO, and pDEP, and AUC-ROC for pNOC, evaluated at +5-minute and +10-minute prediction horizons against the same reference standards used in the primary analysis. Performance thresholds and statistical methods are identical to those applied in the primary performance evaluation.
From the onset of procedural sedation to its completion (estimated duration: 20 to 60 minutes per participant)
Threshold-based Discrimination Performance of pSED, pHYPO, and pDEP Against Predefined Binary Clinical Thresholds
Tidsramme: From the onset of procedural sedation to its completion (estimated duration: 20 to 60 minutes per participant)
AUC-ROC for pSED, pHYPO, and pDEP predictions against binary classifications derived from predefined clinical thresholds (e.g., sedation level categories, hypotension thresholds, respiratory depression criteria)
From the onset of procedural sedation to its completion (estimated duration: 20 to 60 minutes per participant)
Exploratory Subgroup Analyses of Predictive Performance by ASA Physical Status, Age Group, and Sex
Tidsramme: From the onset of procedural sedation to its completion (estimated duration: 20 to 60 minutes per participant)
Discrimination metrics (c-index or AUC-ROC, as applicable) for each SED Pack predictive index compared across predefined patient subgroups: ASA physical status (I/II vs. III), age group (<65 vs. ≥65 years), and sex (male vs. female). These analyses are descriptive and exploratory; the study is not powered for inferential subgroup comparisons.
From the onset of procedural sedation to its completion (estimated duration: 20 to 60 minutes per participant)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Hjelpsomme linker

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

23. juli 2026

Primær fullføring (Antatt)

1. desember 2026

Studiet fullført (Antatt)

1. desember 2026

Datoer for studieregistrering

Først innsendt

29. juli 2026

Først innsendt som oppfylte QC-kriteriene

4. august 2026

Først lagt ut (Faktiske)

6. august 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

6. august 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

4. august 2026

Sist bekreftet

1. juli 2026

Mer informasjon

Begreper knyttet til denne studien

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere